Related Experiment Video
Updated: May 21, 2025
Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
Kidney transplant in patients with C3 glomerulopathy
Rose Mary Attieh1, Joyita Bharati2, Purva Sharma3
1Department of Transplant, Mayo Clinic Jacksonville, FL, USA.
Insights
Complement protein 3 (C3) glomerulopathy (C3G) is a rare kidney disease with high recurrence after kidney transplantation. Research is ongoing for better transplant timing, peri-transplant management, and novel therapies like complement inhibitors to prevent recurrence.
Area of Science:
- Nephrology
- Immunology
- Transplantation
Background:
- Complement protein 3 (C3) glomerulopathy (C3G) is a rare, progressive kidney disease.
- It frequently leads to end-stage kidney disease (ESKD), making kidney transplantation the primary treatment.
- C3G recurrence post-transplantation affects over two-thirds of patients, posing a significant challenge.
Purpose of the Study:
- To address knowledge gaps in optimal timing for kidney transplantation in C3G patients.
- To explore effective peri-transplant management strategies for C3G.
- To review current and emerging therapeutic approaches for recurrent C3G post-transplantation.
Main Methods:
- Review of current understanding of C3G pathophysiology and recurrence factors.
- Analysis of existing treatment strategies, including eculizumab.
- Evaluation of ongoing clinical trials for novel complement inhibitors (factor B and C3 inhibitors).
Main Results:
- Optimal transplant timing and peri-transplant management strategies for C3G remain unclear.
- No definitive link exists between functional complement levels and post-transplant recurrence risk.
- Eculizumab shows inconsistent efficacy; new complement inhibitors are promising but require further investigation.
Conclusions:
- Significant gaps exist in managing C3G patients undergoing kidney transplantation.
- Predictive accuracy for recurrence is limited by variable gene penetrance and genotype-phenotype correlations.
- Emerging complement inhibitors targeting factor B and C3 may offer future therapeutic benefits for recurrent C3G.
Abstract:
Complement protein 3 (C3) glomerulopathy (C3G) is a rare and progressive kidney disease primarily affecting young individuals and frequently advancing to end-stage kidney disease (ESKD). For ESKD, kidney transplantation remains the optimal treatment option; however, C3G has a high recurrence rate post-transplantation, affecting over two-thirds of transplanted patients. Despite advances in our understanding of C3G, significant gaps persist regarding the optimal timing for transplantation and the best strategies for peri-transplant management. Currently, no clear evidence links functional complement levels to the risk of post-transplant recurrence. Genetic counseling is also complex, due to variable gene penetrance and weak genotype-phenotype correlations, which limit predictive accuracy. Transplant-related factors are believed to significantly influence C3G recurrence, yet there are no established methods for preventing recurrence after transplantation. Eculizumab has shown inconsistent efficacy in managing recurrent C3G. However, new proximal complement inhibitors, such as factor B and C3 inhibitors, are under investigation in clinical trials and show promise. Some of these trials include kidney transplant patients with C3G, and their outcomes could potentially shape future treatment protocols.
